EP35: The 1982 Johns-Manville Bankruptcy That Reshaped Mass Tort Law

What Are the Key Facts About the 1982 Johns-Manville Bankruptcy?

The 1982 Manville bankruptcy is the single most important event in the history of American mass tort litigation. Before Manville, no one had filed Chapter 11 to escape mass tort liability while remaining operationally solvent. After Manville, more than 100 companies followed — and Congress codified the playbook into the Bankruptcy Code itself.

For families with a mesothelioma diagnosis today, every asbestos trust fund claim is in some sense a Manville claim — filed under a framework Manville created, processed through procedures Manville's lawyers and the Court invented, and paid at percentages dictated by the same fundamental mismatch Manville first exposed: the gap between projected liability and actual liability when the population of injured workers is an order of magnitude larger than the company projected.

Why Did Profitable Manville File Chapter 11 in 1982?

The traditional purpose of Chapter 11 was to give an operationally distressed business room to restructure debt and emerge as a going concern. Manville did not fit that profile. At the time of filing, the company reported $1,200 million in net worth, $2,200 million in total assets, and $49.2 million in 1982 earnings from continuing operations [1]. The Harvard Law Review's contemporaneous analysis described Manville as a "healthy and solvent corporation" seeking "refuge from potentially massive but speculative tort liability" [7].

The trigger was an accounting requirement, not insolvency. In summer 1982, Manville commissioned an epidemiological study from Epidemiology Resources, Inc. (A. Walker, Projections of Asbestos-Related Disease: 1980–2009, Final Report, August 2, 1982). The study projected at least 30,000 additional asbestos lawsuits over the next 20 years. Combined with the 16,500 existing claims, the total liability exposure was estimated at approximately $2 billion through 2001 [1].

Once the Walker study was distributed to the board, Manville's independent auditors determined the projection created a contingent liability that, under Generally Accepted Accounting Principles, had to be reflected on the balance sheet. A $2 billion entry on the liability side would trigger acceleration clauses in the company's commercial credit agreements. Bankruptcy became the chosen alternative to that acceleration cascade.

CEO John A. McKinney was the central figure. McKinney had been chairman and CEO since May 1977. By 1979 he was spending half of his time on the asbestos problem. He later admitted he had been "emotionally and completely opposed" to bankruptcy before being persuaded by the company's lawyers, led by Senior Vice-President G. Earl Parker [7]. The Board of Directors approved the filing unanimously on August 25, 1982, supported by an affidavit from Manville officer James F. Beasley laying out the strategic rationale [1].

The stated reasons — per McKinney's public statements and the Beasley affidavit — were the projected 20-to-30-year litigation overhang, anticipated unsecured-financing difficulties, gradual business disintegration, and inability to access approximately $600 million in disputed insurance coverage [3].

The structural reason, per the Harvard Law Review, was simpler: Manville was using the bankruptcy power "largely as a tool to limit the aggregate size of its current and future liabilities." The Los Angeles Times observed in 1987 that the filing "triggered public outrage, as many viewed it as a strategy for the company to evade its product-liability obligations" [7]. Congress later modified bankruptcy regulations to prevent other businesses from emulating Manville's approach in unrelated industries, while preserving and codifying the asbestos-specific framework as Section 524(g) in 1994 [11].

Who Was Judge Burton R. Lifland, and Why Did His Rulings Matter?

Burton R. Lifland (September 30, 1929 — January 12, 2014) was a U.S. Bankruptcy Judge for the Southern District of New York, appointed in 1980 [12]. By the early 1990s he was widely called the "dean of the bankruptcy bar." He served as Chief Judge of the Bankruptcy Court SDNY and Chief Judge of the Bankruptcy Appellate Panel for the Second Circuit. His other significant cases included Macy's (1992), Blockbuster Video, Calpine, Dana, and the Bernie Madoff aftermath. He was credited with setting the tone that gave the Manhattan federal court "a reputation as one of the most pro-debtor bankruptcy courts in the nation" [12].

Lifland made two foundational rulings in Manville that, taken together, are the legal foundation of the modern asbestos trust system.

The eligibility ruling. Lifland upheld Manville's right to file Chapter 11 despite being solvent. He reasoned that the "spectre of proliferating, overburdening litigation to be commenced in the next 20-30 years" justified the filing, and that liquidation "would be economically inefficient in not only leaving many asbestos claimants uncompensated, but also in eliminating needed jobs and the productivity emanating from an ongoing concern." This ruling created the template every solvent asbestos defendant has used since — including W.R. Grace in 2001, which used nearly identical language ("financially strong but... best available forum") in its own Chapter 11 filing.

The future-claims ruling. Lifland's landmark holding was that future asbestos claims — by people not yet diagnosed with mesothelioma or asbestosis — were cognizable "claims" under Section 101(4) of the Bankruptcy Code. He held that Congress specifically intended to afford "the broadest possible scope to the definition of 'claim.'" Since "a vast group of future claimants will exist" as "a statistical certainty," and these claims were the "raison d'être for the filing," they had to be dealt with in the Chapter 11 case [12].

The future-claims ruling was the breakthrough. Without it, the Trust structure could not have discharged the claims of victims whose disease had not yet manifested — and asbestos has latency periods of 20 to 50 years. To represent those unborn claims, Lifland appointed New York attorney Leon Silverman as the court-appointed Legal Representative for Future Claimants. Silverman proposed key elements of the final reorganization plan and is one of the unsung architects of the modern asbestos compensation system [13].

How Did the Manville Trust Work, and Why Was It Never Enough?

The Manville Personal Injury Settlement Trust became operational on November 28, 1988, after the U.S. Court of Appeals for the Second Circuit confirmed the Plan of Reorganization on October 28, 1988. The Trust was a grantor trust — the first of its kind. There was, in the Trust Executive Director's words, "no precedent" for its structure.

The funding totaled approximately $2,500 million in face value:

Funding Source	Amount
Cash from Manville	$150 million (plus $5.4 million accrued interest)
Insurance settlement proceeds	$695 million (including $72 million interest)
Manville Common Stock	24 million shares (50% of outstanding)
Convertible preferred stock	7.2 million shares (Trust receives 80% ownership after conversion)
Bonds	Two bonds with aggregate face value exceeding $1,800 million
Profit-sharing rights	Up to 20% of Manville's profits beginning 1992

The Trust's Executive Director was Marianna S. Smith, who authored the definitive published analysis of the Trust's operations. Trustees were appointed by the bankruptcy court in January 1987 and held to the "highest standards of care" — a standard stricter than the corporate "reasonable business judgment" rule. Trustee insurance required separate D&O coverage at annual premiums over $2 million plus $30 million in self-insured reserves. Claims processing was handled by Claims Resolution Management Corporation (CRMC) [14].

The original Plan promised that all claimants would receive 100% of full value. That promise collapsed almost immediately. Trust planners had projected approximately 50,000 claimants at roughly $40,000 each. By mid-1989, 65,000 claims had been filed. By August 1989, the figure exceeded 97,000. By January 1991, more than 170,000 claims had been filed [13]. By 2026, the cumulative total exceeds 1 million.

The pro rata payment percentage has been adjusted repeatedly to reflect the structural mismatch between projected and actual claim volume:

Date	Pro Rata Payment	Trigger
1988–1989	100%	Pre-bankruptcy claims paid in full
Early 1990	40% at settlement + 60% over 5 years	Trust announced extended payment plan
July 1990	Freeze	Court imposed payments freeze
1995	10%	TDP established the pro rata percentage
June 2001	5%	Reduced on interim basis
March 2008	7.5%	Raised after Trust reassessment
August 2014	6.25%	Lowered
November 2016	5.1%	Lowered to current rate
2026	5.1%	Applies to all disease categories [15]

The collapse from 100% to 5.1% is the central financial fact of the Manville Trust. A mesothelioma claimant under the current Trust Distribution Procedures (TDP) is classified at Level VIII, with a scheduled value of $350,000 and a 2026 payout of approximately $17,850 [15]. This is why mesothelioma cases today are never single-trust matters — they are coordinated filings across 60+ active asbestos trust funds plus active-defendant litigation.

What Did Section 524(g) Make Possible for Other Companies?

Section 524(g) was added to the U.S. Bankruptcy Code in 1994 as part of the Bankruptcy Reform Act. Its purpose was to codify the Manville model: a debtor company facing crushing asbestos liability can channel all present and future asbestos personal-injury claims into a trust, in exchange for a permanent injunction barring suits against the debtor and certain protected non-debtor third parties [11].

The statute imposed specific procedural requirements borrowed directly from the Manville case: court-appointed legal representative for future claimants, supermajority approval of the plan by present claimants (typically 75%), and a finding that the trust is necessary to deal with future demands. The structure was unique to asbestos — Congress did not extend it to other mass torts, though the federal courts have applied analogous reasoning in non-asbestos contexts like Dalkon Shield (A.H. Robins) and silicone breast implants (Dow Corning).

As of 2026, more than 60 active 524(g) trusts hold an estimated $30 billion in combined assets [13]. The list of post-Manville asbestos bankruptcies includes most of the historic U.S. asbestos manufacturers: W.R. Grace (filed 2001), Owens-Corning (2000), Babcock & Wilcox, Combustion Engineering, Armstrong World Industries, Federal-Mogul, Halliburton, Honeywell, Kaiser Aluminum, North American Refractories, Pittsburgh Corning, Plibrico, USG Corporation, and dozens of smaller suppliers and contractors.

The economic effect of Section 524(g) is the parallel-track structure of modern mesothelioma compensation. Most claims today are filed simultaneously against (a) multiple trust funds for bankrupt manufacturers and (b) the solvent companies that remain in the active-defendant pool. Without Manville and Section 524(g), the asbestos compensation system would either look like an even more chaotic flood of individual lawsuits, or would have collapsed under the projected claim volume. The trust system is structurally underfunded — that is the 5.1% payment ratio's plain meaning — but it is at least an organized, predictable underfunding rather than an unmanaged litigation lottery.

How Has Berkshire Hathaway's 2001 Acquisition Affected Mesothelioma Cases?

On December 20, 2000, Warren Buffett's Berkshire Hathaway announced it would acquire Johns Manville Corporation for $2,400 million in cash, approximately $13 per share [4]. The agreement followed the collapse of an earlier deal that valued the company at $15.63 per share, which the prior buyer abandoned [6]. The acquisition closed in 2001.

Crucially, Berkshire bought only the post-reorganization operating company. The Manville Personal Injury Settlement Trust was a separate entity created by the 1986 Plan of Reorganization, and remained separate after the Berkshire acquisition. Berkshire's $2.4 billion paid the Trust for the Trust's 80% equity stake in the company plus minority shareholders — converting the Trust's stock holdings to cash. The Trust used the proceeds for ongoing claim payments, but the conversion did not increase the total funds available to victims relative to projected claim volume.

For mesothelioma families, the practical reality is unchanged from before the Berkshire deal. Manville Trust scheduled values and pro rata payment percentages are set by the Trust Distribution Procedures, not by the underlying operating company's ownership. The Berkshire acquisition is a milestone in corporate history; it is not a milestone in victim compensation.

The Trust still holds approximately $620 million in remaining assets as of recent reporting. Total cumulative payouts since 1988 exceed $5 billion [15]. The Trust will continue paying mesothelioma claims for as long as new diagnoses occur — which, given asbestos latency periods of 20 to 50 years, is projected to continue well into the 2040s and beyond.

What Does the Manville Bankruptcy Mean for Mesothelioma Cases in 2026?

Three concrete consequences of the 1982 filing are still load-bearing in modern mesothelioma practice.

First, the Manville Trust is rarely the only filing. The 5.1% pro rata percentage means a mesothelioma claim against Manville alone returns roughly $17,850 on a $350,000 scheduled value. That sum does not approach mesothelioma's true economic and human cost. Effective mesothelioma representation requires coordinated filings across every applicable 524(g) trust the victim's exposure history can document, plus active-defendant lawsuits against companies that did not file for bankruptcy. The asbestos trust fund system is structurally designed for parallel filings, not single-trust resolution.

Second, the "knew or should have known" record matters at the trust stage too. Trust claim forms require documentation of exposure to specific products. The 1935 Lanza study suppression, the 1927 BMJ papers, and the broader corporate-knowledge record support not just punitive damages against active defendants, but also evidence packages for trust filings where the claim must show both exposure to the specific bankrupt company's product and the company's awareness of the hazard at the relevant time.

Third, the system rewards experienced counsel. 524(g) trust filings are procedurally distinct from civil litigation. Each trust has its own TDP, scheduled values, evidence requirements, and pro rata percentage. A mesothelioma family pursuing the full available compensation needs counsel who routinely files across multiple trusts, identifies eligible defendants from work history and product identification, and coordinates statute-of-limitations timing — mesothelioma SOLs run from diagnosis date, generally one to three years, depending on state. Mesothelioma attorneys who handle these matters routinely understand the trust-fund interaction with active litigation; general practitioners typically do not.

For families with a recent Johns Manville exposure history, the practical path is straightforward: document the work history with as much specificity as the family can reconstruct, gather any product identification (photographs, receipts, coworker statements), and consult a mesothelioma attorney before any statute-of-limitations deadline. The Manville Trust is a 1988 invention still operating in 2026 because the underlying asbestos exposure problem it was created to address has not ended — and the legal infrastructure McKinney, Lifland, and Silverman built is what makes compensation possible at all, even at 5.1%.

Where Can You Find the Original Sources and Further Reading?

The 1982 Manville bankruptcy is one of the most thoroughly documented corporate events in American legal history — generating roughly 1,000 pages of scholarly analysis across half a dozen major law reviews. The standard contemporaneous legal analysis is the Notre Dame Law School scholarship paper "The Manville Bankruptcy: Treating Mass Tort Claims in Chapter 11 Proceedings" (1983), which dissected the filing as it unfolded [8]. The definitive analysis of the Trust's operations is the Duke University Law and Contemporary Problems article "Resolving Asbestos Claims: The Manville Personal Injury Settlement Trust" (1990), authored by Trust Executive Director Marianna S. Smith [9]. The University of Pennsylvania Law Review's "Relief from Tort Liability through Reorganization" (1986) places the case in the broader scholarship on Chapter 11 strategic uses [10]. The NYU School of Law's "The Case for Broad Access to 11 U.S.C. § 524(g)" (2014) is the most recent legal scholarship on the modern statutory framework [11]. Contemporary press coverage in the Los Angeles Times [5][6][7] tracked the unfolding strategy from the August 1982 filing through the 2000 Berkshire acquisition; the broader corporate history is compiled across the encyclopedic and scholarly sources [1][2][3][4]. Wikipedia's biographical entry on Judge Burton R. Lifland [12] and the entry on Asbestos bankruptcy trusts [13] provide the contextual overview. The WikiMesothelioma Johns-Manville Corporate History [16] page compiles the surrounding corporate and exposure history.